Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | PHASE1 | COMPLETED | 33 | — | — | May 23, 2017 | Jan 13, 2021 | Aug 25, 2021 | 24 | Austria, Czechia +4 |
Defined as the number of participants achieving a complete response (CR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 1.
Defined as the number of participants achieving a confirmed, stringent complete response (sCR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 2.
| Arm | Type | Description |
|---|---|---|
| Single arm Study MP0250 plus BOR + DEX | EXPERIMENTAL | Single arm study of MP0250 plus bortezomib + dexamethasone |
| Name | Type | Description |
|---|---|---|
| MP0250 plus BOR+DEX | BIOLOGICAL | 6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label. Number of Cycles: until progression or unacceptable toxicity develops. |
Inclusion Criteria: 1. Patients with MM who have received: * Part 1 ≥2 lines of therapy (including bortezomib and an IMiD) and have shown no response (i.e. stable disease) to, have progressed on the most recent treatment or have progressed within 60 days of the most recent therapy * Part 2 ≥...